Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy Designation for PM359 for the Treatment of Chronic Granulomatous Disease
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
RETRANSMISSION: LaFleur Minerals and Trafigura Progress Toward Definitive Agreement, Beacon Gold Mill Nearing Gold Production Restart
